Immunic (IMUX) Net Equity Issued and Repurchased (2016 - 2024)

Immunic has reported Net Equity Issued and Repurchased for 9 years, with the latest figure at $191000.0 in Q1 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $191000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $191000.0 (down 78.07% YoY) and the FY2024 annual result came in at $191000.0, down 77.61% from the prior year.
• Net Equity Issued and Repurchased eased to $191000.0 in Q1 2024 per IMUX's latest filing, from $571000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $73.5 million in Q4 2020 and troughed at -$41.3 million in Q4 2021.
• A 5-year average of $12.5 million and a median of $2.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2020 and 2021: Net Equity Issued and Repurchased jumped 9355.14% in 2020, then sank 156.18% in 2021.
• Over 5 years, Net Equity Issued and Repurchased stood at $73.5 million in 2020, then tumbled by 156.18% to -$41.3 million in 2021, then jumped by 100.04% to $16000.0 in 2022, then soared by 3468.75% to $571000.0 in 2023, then slumped by 66.55% to $191000.0 in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $191000.0, $571000.0, and $300000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.